Company Overview and News

 
BTU Clarifies Previous Release Regarding Acquiring Two Strategic Properties Contiguous to Great Bear's Dixie Project, Red Lake District, Canada

2018-10-17 accesswire
VANCOUVER, BC / ACCESSWIRE / October 17, 2018 / BTU METALS CORP. ("BTU" or the "Company") (TSX-V: BTU) is pleased to announce it has entered into two agreements with arms-length vendors to acquire two strategic properties, both adjoining and contiguous to the south and south-west border of Great Bear Resources Corp.'s (GBR) Dixie Project located in the Red Lake District of Ontario.
GTBDF GBR

 
Great Bear Resources encouraged by more positive drill results from Dixie Project

2018-09-28 proactiveinvestors.com.au
Great Bear Resources (CVE:GBR) President and CEO Chris Taylor joined Steve Darling in the Proactive Investors Vancouver studios to highlight positive results from their Dixie Project.
GTBDF GBR

2
Rob McEwen and McEwen Mining File Early Warning Reports in Connection With a Private Placement in Great Bear Resources Ltd.

2018-09-11 globenewswire - 1
TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Rob McEwen, through his wholly owned company Evanachan Limited (“Evanachan”), and McEwen Mining Inc. (“MUX”) have subscribed today for 3,930,932 Units (the “Units”) of Great Bear Resources Ltd. (“GBR”) of 1020-800 West Pender Street, Vancouver, BC, V6C 2V6 at a price of $1.45 per Unit for an aggregate gross investment of $5,699,851.40. The subscriptions by Evanachan and MUX were made by way of private placement, which formed part of a larger offering by GBR on the same terms (the “Offering”).
MUX.RTWI GTBDF MUX GBR MUX

13
Gold Mining Bull: Top News For August 2018

2018-09-01 seekingalpha
Coeur Mining made a move to buy a heap leach gold deposit in Nevada; Northern Star goes to Alaska for its next mine.
RIO RIO GTBDF KGI.DB NST FCX BFDRF GSV NSU BFD RTPPF MUX.RTWI RTNTF MUX GG KL SAND SSL SDDXF KGI MUX KGI.DB.A CDEUW NULGF SNXZF PSPGF NESRF CDE RIO GBR NHRNY

 
Boring, Then Not Boring: What Happens When A Junior Gold Miner Gets It Right

2018-08-28 seekingalpha
Back in June Jay Taylor's Gold, Energy & Tech Stocks newsletter published a nice write-up on a junior gold miner called Great Bear Resources (OTCPK:GTBDF), which included the following:
GTBDF GBR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...